SEARCH

SEARCH BY CITATION

Keyword index

  1. Top of page
  2. Keyword index
  • 24-hr oesophageal and intragastric pH, 455
  • 5-aminosalicylates, 179
  • 5-HT1 receptor agonism, 805
  • 6-mercaptopurine, 679
  • 6-thioguanine nucleotides, 1269
  • 6-tioguanine, 1269
  • 90 years, 1153
  • Abraha, H. see Pereira, S.P.
  • Abraham, N.S., Moayyedi, P., Daniels, B. & Veldhuyzen Van Zanten, S.J.O. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia, 631
  • Achem, S.R. see Ward, E.M.
  • Acid Suppression, 591, 655
  • Acidity index, 443
  • Adam, V. see Barkun, A.N.
  • Adefovir, 25
  • Adverse drug reaction, 303
  • Ageing, 39
  • Aguirre, T. see El-Serag, H.B.
  • Aichbichler, B.W. see Wenzl, H.H.
  • Aithal, G.P., Haugk, B., Das, S., Card, T., Burt, A.D. & Record, C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? 391
  • Alahuddin, S. see Kaptan, K.
  • Alahuddin, S. see Rajendra, S.
  • Albanese, A. see Brisinda, G.
  • Alicaforsen, 281
  • Aloe vera, 739
  • Amantadine, 339
  • Ammon, S. see Treiber, G.
  • Amoruso, A. see De Francesco, V.
  • Anal fissure, 481
  • Andreyev, H.J.N. see Lindsay, J.O.
  • Andrieux, C. see Bouhnik, Y.
  • Andriulli, A. see Mangia, A.
  • Angelico, F. see Angelico, M.
  • Angelico, M., Cepparulo, M., Angelico, F., Francioso, S., Barlattani, A., Di Candilo, F., Della Vecchia, R., Demelia, L., De Sanctis, G., Gentile, S., Grieco, A., Parruti, G., Sabusco, G., Tarquini, L., Tosti, A. & Zaru, S. The SMIEC 1 Group. A randomized controlled trial of amantadine plus interferon-α2a vs. interferon-α2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-α2a monotherapy, 339
  • Annibale, B. see Panzuto, F.
  • Antibiotic, 789
  • Antibiotic resistance, 1009, 1315
  • Antibiotic treatment, 1315
  • Antidopaminergic prokinetics, 379
  • Antisense, 281
  • Antro-pyloro-duodenal motility, 805
  • APC gene, 1225
  • Apolinario, A., Diago, M., Lo Iacono, O., Lorente, R., Pérez, C., Majano, P.L., Clemente, G. & García-Monzón, C. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy, 551
  • Apoptosis, 1225
  • Appropriateness, 197
  • Arden, N.K. see Trebble, T.M.
  • Arguedas, M.R. see Raines, D.L.
  • Armstrong, D. see Chiba, N.
  • Armstrong, D. see Stanghellini, V.
  • Armuzzi, A. see Candelli, M.
  • Arterial embolization, 999, 1301
  • Asacol, 1089
  • Aspirin, 39, 359, 1099
  • Atrophic gastritis, 107
  • Austin, A.S., Mahida, Y.R., Clarke, D., Ryder, S.D. & Freeman, J.G. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis, 79
  • Autoimmune liver diseases, 209
  • Axon, A.T.R. Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease – an alternative hypothesis, 253
  • Azathioprine, 295, 679, 1147
  • Baccini, F. see Panzuto, F.
  • BAclofen, 1041
  • Bacterial virulence factors, 219
  • Baier, P. see Büning, C.
  • Bailey, D.M. see Kitiyakara, T.
  • Baird, A.W. see O'Keeffe, C.
  • Balsalazide, 1089
  • Bane, B. see Miner Jr, P.
  • Bardhan, K.D. see Stanghellini, V.
  • Bardou, M. see Barkun, A.N.
  • Barkun, A. see Chiba, N.
  • Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. & Bardou, M. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis, 591
  • Barlattani, A. see Angelico, M.
  • Barone, M. see De Francesco, V.
  • Bautista, J., Fullerton, H., Briseno, M., Cui, H. & Fass, R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain – a randomized, double-blind, placebo-controlled, crossover trial, 1123
  • Belaiche, J. see Louis, E.
  • Benazzato, L. see Di Sabatino, A.
  • Benöhr, P. see Raddatz, D.
  • Benson, M.J. see Kang, J.Y.
  • Bentivoglio, A.R. see Brisinda, G.
  • Berloco, P. see De Francesco, V.
  • Bernstein, C.N. & Leslie, W.D. Review article: osteoporosis and inflammatory bowel disease, 941
  • Beyan, C. see Kaptan, K.
  • Biancone, L., Tosti, C., Geremia, A., Fina, D., Petruzziello, C., Emerenziani, S. & Pallone, F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial, 755
  • Bifidobacterium, 889
  • Bijkerk, C.J., Muris, J.W.M., Knottnerus, J.A., Hoes, A.W. & De Wit, N.J. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome, 245
  • Bilardi, C. see Zentilin, P.
  • Biliary disorders, 209, 563, 601, 901, 1153, 1293
  • Binder, V. see Jess, T.
  • Biofeedback, 829
  • Biological therapy, 749
  • Biomarker, 797
  • Bjorkman, D. see Loftus Jr, E.V.
  • Bleeding, 1051
  • Blonska-Fajfrowska, B. see Mangel, A.W.
  • Bloom, S., Kiilerich, S., Lassen, M.R., Forbes, A., Leiper, K., Langholz, E., Irvine, E.J., O'Morain, C., Lowson, D. & Orm, S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis, 871
  • Blumenstein, I. see Schröder, O.
  • Bochow, B. see Büning, C.
  • Bockemühl, M. see Raddatz, D.
  • Bone, 1063
  • Bone biochemical markers, 563
  • Bone densitometry, 563
  • Borrelli, F., Capasso, R., Russo, A. & Ernst, E. Systematic review: green tea and gastrointestinal cancer risk, 497
  • Botulinum toxin, 695
  • Bouhnik, Y., Neut, C., Raskine, L., Michel, C., Riottot, M., Andrieux, C., Guillemot, F., Dyard, F. & Flourié, B. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation, 889
  • Bouras, E.P. see Ward, E.M.
  • Bradley, J. see Miner Jr, P.
  • Bramble, M.G. see Panter, S.J.
  • Branca, G. see Cammarota, G.
  • Brandara, F. see Brisinda, G.
  • Briseno, M. see Bautista, J.
  • Brisinda, G., Albanese, A., Cadeddu, F., Bentivoglio, A.R., Mabisombi, A., Marniga, G. & Maria, G. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized ‘Botox vs. Dysport’ controlled trial, 695
  • Brisinda, G., Cadeddu, F., Brandara, F., Maria, G., Halphen, M., Chaussade, S., Minic´, M., Guslandi, M., Cheung, O. & Wald, A. Letters to the editors, 1131
  • Bruley Des Varannes, S. see Galmiche, J.P.
  • Bruley des Varannes, S. see Zerbib, F.
  • Brune, K. see Dormann, H.
  • Buch, A. see Sandborn, W.J.
  • Bueno De Mesquita, M. see Marchal, L.
  • Bühner, S. see Büning, C.
  • Büning, C., Genschel, J., Bühner, S., Krüger, S., Kling, K., Dignass, A., Baier, P., Bochow, B., Ockenga, J., Schmidt, H.H.-J. & Lochs, H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation, 1073
  • Burattini, O. see De Francesco, V.
  • Burggraaf, J. see Kamerling, I.M.C.
  • Burt, A.D. see Aithal, G.P.
  • Buxton-Thomas, M. see Pereira, S.P.
  • Cadeddu, F. see Brisinda, G.
  • CagA, 407
  • Calder, P.C. see Trebble, T.M.
  • Calvert, E.L., Whorwell, P.J. & Houghton, L.A. Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism, 805
  • Calvet, X. see Gisbert, J.P.
  • Camellia sinensis, 497
  • Camilleri, M. see Cremonini, F.
  • Cammarota, G., Martino, A., Pirozzi, G., Cianci, R., Branca, G., Nista, E.C., Cazzato, A., Cannizzaro, O., Miele, L., Grieco, A., Gasbarrini, A. & Gasbarrini, G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection, 789
  • Cancer, 879
  • Candelli, M. see Santarelli, L.
  • Candelli, M., Armuzzi, A., Nista, E.C., Fini, L., Gasbarrini, G. & Gasbarrini, A. Letter to the Editors, 243
  • Cannizzaro, O. see Cammarota, G.
  • Capasso, R. see Borrelli, F.
  • Caprai, S. see Sciveres, M.
  • Capsaicin, 415
  • Capurso, G. see Panzuto, F.
  • Carballo, F. see Gisbert, J.P.
  • Card, T. see Aithal, G.P.
  • CARD15, 1073
  • Case-control study, 817
  • Cash, B.D. & Chey, W.D. Review article: irritable bowel syndrome – an evidence-based approach to diagnosis, 1235
  • Castell, D.O. see Tutuian, R.
  • Castle, M.Z.D., Silk, D.B.A. & Libby, G.W. Review article: the rationale for antidepressant therapy in functional gastrointestinal disorders, 969
  • Cazzato, A. see Cammarota, G.
  • CCK, 601
  • Celiac disease, 1199
  • Ceppa, P. see Zentilin, P.
  • Cepparulo, M. see Angelico, M.
  • Chan, A.O. see Hui, C.-K.
  • Chan, A.O.O. see Lam, C.-M.
  • Chan, A.O.O. see Wong, W.M.
  • Chan, A.O.O., Yuen, M.F., Lam, C.M., Fong, C.Y., Wong, B.C.Y. & Lai, C.L. Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong, 401
  • Chan, F.K.L. & Graham, D.Y. Review article: prevention of non-steroidal antiinflammatory drug gastrointestinal complications – review and recommendations based on risk assessment, 1051
  • Chan, H.L.-Y. see Wong, V.W.-S.
  • Chan, S.-C. see Hui, C.-K.
  • Chang, C.-M. see Ng, F.-H.
  • Chang, F.-Y. see Huo, T.
  • Chang, F.-Y. see Huo, T.-I.
  • Chang, L. see Schwetz, I.
  • Charles, F. see Zerbib, F.
  • Chaussade, S. see Brisinda, G.
  • Chayama, K. see Kai, H.
  • Chelators, 157
  • Chemokines, 551
  • Chemoprotective substance, 497
  • Chen, H.X. see Xiong, L.S.
  • Chen, M.H. see Xiong, L.S.
  • Chen, S.C. & Rex, D.K. Review article: registered nurse-administered propofol sedation for endoscopy, 147
  • Chen, W.-H. see Ng, F.-H.
  • Cheung, O. see Brisinda, G.
  • Cheung, O. & Wald, A. Review article: the management of pelvic floor disorders, 481
  • Cheung, W.W. see Hui, C.-K.
  • Chey, W.D. see Cash, B.D.
  • Chiang, J.-H. see Huo, T.
  • Chiang, J.-H. see Huo, T.-I.
  • Chiba, N., Veldhuyzen Van Zanten, S.J.O., Escobedo, S., Grace, E., Lee, J., Sinclair, P., Barkun, A., Armstrong, D. & Thomson, A.B.R. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia, 349
  • Chinn, D.J. see Rubin, G.P.
  • Chiu, Y.-L. see Freston, J.W.
  • Cholecystokinin, 1261
  • Cholestasis, 1293
  • Chronic hepatitis B, 25
  • Chronic hepatitis C, 339
  • Chronic Intestinal Pseudo-Obstruction, 687
  • Chronic liver disease, 715
  • Chronic viral hepatitis B, 323
  • Cianci, R. see Cammarota, G.
  • Ciccocioppo, R. see Di Sabatino, A.
  • Cipollina, L. see Tonini, M.
  • Cirrhosis, 391, 1159
  • Clarithromycin, 993, 1009
  • Clarke, D. see Austin, A.S.
  • Clemente, G. see Apolinario, A.
  • Clinical alert, 303
  • Clopidogrel, 359
  • Cluster analysis, 133
  • Coeliac disease, 1277
  • Cohen, A.F. see Kamerling, I.M.C.
  • Cohort study, 679
  • Colitis, 167, 871
  • Collin, P., Thorell, L., Kaukinen, K. & Mäki, M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? 1277
  • Colombel, J.-F. see Louis, E.
  • Colon, 765
  • Colonic diverticular disease, 765
  • Colonoscopy, 765
  • Colorectal cancer, 1, 287
  • Colquhoun, S. see Firpi, R.J.
  • Complementary therapy, 521
  • Complications, 1051
  • Computer assisted signal processing, 303
  • Congenital abnormalities, 679
  • Constipation, 481, 889
  • Copper, 157
  • Corazza, G.R. see Di Sabatino, A.
  • Corazza, G.R. see Tonini, M.
  • Cost analysis, 349
  • Cost-benefit analysis, 1247
  • Cost-effectiveness, 349, 591
  • Cost-effectiveness analysis, 571, 1199
  • Cotler, S.J. see Jensen, D.M.
  • Courtney, E.D.J., Melville, D.M. & Leicester, R.J. Review article: chemoprevention of colorectal cancer, 1
  • COX-2 inhibitors, 197, 1051
  • COX-2 selective inhibitors, 817
  • Crema, F. see Tonini, M.
  • Cremonini, F. see Santarelli, L.
  • Criegee-Rieck, M. see Dormann, H.
  • Crohn's disease, 287, 295, 427, 511, 671, 953, 1019, 1073, 1147, 1269
  • Cui, H. see Bautista, J.
  • Culture-guided, 789
  • Cyclosporin A, 209
  • CYP2C19, 113
  • Cytokine(s), 671, 1063
  • D2 receptor blockade, 379
  • Dagalp, K. see Uygun, A.
  • Dahlerup, J.F. see Vilien, M.
  • Dall'Ozzo, S. see Louis, E.
  • D'Ambra, G. see Panzuto, F.
  • Dammann, H.-G., Saleki, M., Torz, M., Schulz, H.-U., Krupp, S., Schürer, M., Timm, J. & Gessner, U. Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects 367
  • Daniels, B. see Abraham, N.S.
  • Das, S. see Aithal, G.P.
  • Davis, D.M. see Ward, E.M.
  • Davis, K.J. see Higgins, P.D.R.
  • De Francesco, V., Della Valle, N., Stoppino, V., Amoruso, A., Muscatiello, N., Panella, C. & Ierardi, E. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia, 993
  • De Francesco, V., Zullo, A., Margiotta, M., Marangi, S., Burattini, O., Berloco, P., Russo, F., Barone, M., Di Leo, A., Minenna, M.F., Stoppino, V., Morini, S., Panella, C., Francavilla, A. & Ierardi, E. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure, 407
  • De Kam, M.L. see Kamerling, I.M.C.
  • De Ponti, F. see Tonini, M.
  • De Sanctis, G. see Angelico, M.
  • De Silva, A. see Langmead, L.
  • De Vos, M. see Louis, E.
  • De Wit, N.J. see Bijkerk, C.J.
  • Decision analysis, 1247
  • Deibert, P. see Herrlinger, K.R.
  • Delayed diagnosis, 981
  • Delgado-Aros, S. see Cremonini, F.
  • Della Valle, N. see De Francesco, V.
  • Della Vecchia, R. see Angelico, M.
  • Delle Fave, G. see Panzuto, F.
  • Demarchi, B. Vos R. Deprez P. Janssens J. Tack J. Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal, 1261
  • Demelia, L. see Angelico, M.
  • Deprez, P. see Demarchi, B.
  • Devault, K.R. see Ward, E.M.
  • Deveci, S. see Uygun, A.
  • Developing country, 1315
  • D'Haens, G. see Marchal, L.
  • Dhar, A. see Kang, J.Y.
  • D'Hoore, A. see Marchal, L.
  • Di Candilo, F. see Angelico, M.
  • Di Caro, S., Delgado-Aros, S., Sepulveda, A., Gasbarrini, G., Gasbarrini, A. & Camilleri, M. Notice of retraction of article. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease, 145
  • Di Caro, S. see Cremonini, F.
  • Di Giulio, E. see Panzuto, F.
  • Di Leo, A. see De Francesco, V.
  • Di Sabatino, A., Ciccocioppo, R., Benazzato, L., Sturniolo, G.C. & Corazza, G.R. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients, 1019
  • Diagnosis, 157, 829, 923
  • Diago, M. see Apolinario, A.
  • Diaz-Rubio, M., Moreno-Elola-Olaso, C., Rey, E., Locke III, G.R. & Rodriguez-Artalejo, F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population, 95
  • Dietary fiber, 245
  • Dietary supplements, 245
  • Dignass, A. see Büning, C.
  • Disease management, 63
  • Dixon, A. see Todd, J.A.
  • Dominguez-Muñoz, E. see Gisbert, J.P.
  • Donnelly, J.R. see Gremse, D.A.
  • Dormann, H., Criegee-Rieck, M., Neubert, A., Egger, T., Levy, M., Hahn, E.G. & Brune, K. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology, 303
  • Double-blinded randomized controlled study, 455
  • Doxycycline, 789
  • Drug effects, 679
  • Drug safety, 179, 679
  • Drug-induced, 391
  • Drug-resistant mutants, 323
  • Dubois, R.W. see Graham, D.Y.
  • Dubois, R.W., Melmed, G.Y., Henning, J.M. & Laine, L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy, 197
  • Ducrotté, P. see Galmiche, J.P.
  • Dulbecco, P. see Zentilin, P.
  • Dupont, A.W. see Raines, D.L.
  • Dwarakanath, D. see Rubin, G.P.
  • Dyard, F. see Bouhnik, Y.
  • Dyspepsia, 233, 917, 1099
  • Dysplasia, 879
  • Early response, 339
  • Economic evaluation, 349
  • Egger, T. see Dormann, H.
  • El Ghoul, Z. see Louis, E.
  • El-Serag, H.B., Aguirre, T., Kuebeler, M. & Sampliner, R.E. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy, 1255
  • El-Serag, H.B., Pilgrim, P. & Schoenfeld, P. Systematic review: natural history of irritable bowel syndrome, 861
  • El-Serag, H.B. & Talley, N.J. Systematic review: the prevalence and clinical course of functional dyspepsia, 643
  • Emerenziani, S. see Biancone, L.
  • Emmanuel, A.V., Shand, A.G. & Kamm, M.A. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response, 687
  • Empirical trial, 1123
  • Endoscopic retrograde cholangiopancreatography, 1153
  • Endoscopy, 989
  • Enteral stent, 901
  • Epidemiological studies, 497
  • Epidemiology, 233, 287, 1025, 1217
  • Eradication, 219
  • Eradication predictors, 407
  • Eradication therapy, 1181
  • Erdmann, J., Lippl, F., Klose, G. & Schusdziarra, V. Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations, 1173
  • Ernst, E. see Borrelli, F.
  • Erythromycin, 687
  • Escobedo, S. see Chiba, N.
  • Eslick, G.D., Howell, S.C., Hammer, J. & Talley, N.J. Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample, 133
  • Esomeprazole, 655, 1105
  • Etest, 1315
  • Ethnic differences, 765
  • Evidence based medicine, 1235
  • Extrapyramidal reactions, 379
  • Factor analysis, 133
  • Faecal, 923
  • Faecal continence, 311
  • Faecal incontinence, 829
  • Faeces, 923
  • Failure of medical therapy, 1079
  • Fakheri, H., Merat, S., Hosseini, V. & Malekzadeh, R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication, 89
  • Fallingborg, J. see Vilien, M.
  • Fallone, C.A. see Barkun, A.N.
  • Fan, S.-T. see Hui, C.-K.
  • Fan, S.T. see Lam, C.-M.
  • Fan, S.-T. see Poon, R.T.-P.
  • Färkkilä, M.A. see Koivisto, T.T.
  • Fass, R. see Bautista, J.
  • Fatty liver, 537
  • Feakins, R.M. see Langmead, L.
  • Fellermann, K. see Herrlinger, K.R.
  • Fennell, J.M. see Ho, G.T.
  • Ferenci, P. Review article: diagnosis and current therapy of Wilson's disease, 157
  • Ferrante, M. see Marchal, L.
  • Fett, S.L. see Halder, S.L.S.
  • Fickert, P. see Wenzl, H.H.
  • Fina, D. see Biancone, L.
  • Fine, D.R. see Trebble, T.M.
  • Fini, L. see Candelli, M.
  • Fiocca, R. see Zentilin, P.
  • Fiorentini, P. see Galmiche, J.P.
  • Firpi, R.J., Tran, T.T., Flores, P., Nissen, N., Colquhoun, S., Shackleton, C., Martin, P., Vierling, J.M. & Poordad, F.F. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent, 1033
  • Fischer, C. see Herrlinger, K.R.
  • Fissure-in-ano, 695
  • Fistula, 295
  • Fleig, W.E. see Herrlinger, K.R.
  • Flores, P. see Firpi, R.J.
  • Flourié, B. see Bouhnik, Y.
  • Fong, C.Y. see Chan, A.O.O.
  • Forbes, A. see Bloom, S.
  • Fox, M., Thumshirn, M., Menne, D., Stutz, B., Fried, M. & Schwizer, W. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat, 311
  • Fragmentation, 545
  • Francavilla, A. see De Francesco, V.
  • Francioso, S. see Angelico, M.
  • Freeman, J.G. see Austin, A.S.
  • Freston, J.W., Pilmer, B.L., Chiu, Y.-L., Wang, Q., Stolle, J.C., Griffin, J.S. & Lee, C.Q. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole, 1111
  • Fried, M. see Fox, M.
  • Friis, S. see Nørgård, B.
  • Fullerton, H. see Bautista, J.
  • Functional colonic diseases, 245
  • Functional dyspepsia, 219, 631, 643, 797
  • Functional gastrointestinal disorders, 133, 1235
  • Furazolidone, 89
  • Gabrielli, M. see Santarelli, L.
  • Gallbladder, 797
  • Gallbladder motility, 601
  • Gallstone formation, 601
  • Galmiche, J.-P. see Zerbib, F.
  • Galmiche, J.P., Bruley Des Varannes, S., Ducrotté, P., Sacher-Huvelin, S., Vavasseur, F., Taccoen, A., Fiorentini, P. & Homerin, M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers, 655
  • Gambaro, C. see Zentilin, P.
  • García-Monzón, C. see Apolinario, A.
  • Gasbarrini, A. see Cammarota, G.
  • Gasbarrini, A. see Candelli, M.
  • Gasbarrini, A. see Cremonini, F.
  • Gasbarrini, A. see Santarelli, L.
  • Gasbarrini, G. see Cammarota, G.
  • Gasbarrini, G. see Candelli, M.
  • Gasbarrini, G. see Cremonini, F.
  • Gasbarrini, G. see Santarelli, L.
  • Gastric accommodation, 415, 1261
  • Gastric acid, 1105
  • Gastric acid secretion, 253, 1181
  • Gastric adenocarcinoma, 841
  • Gastric barostat, 1261
  • Gastric carcinoma, 989
  • Gastric mucosal atrophy, 1181
  • Gastric outflow obstruction, 901
  • Gastric pH, 655
  • Gastric sensitivity, 415, 1261
  • Gastric tachyarrhythmia, 583
  • Gastric tone, 415
  • Gastric ulcer, 989
  • Gastroesophageal reflux disease, 463
  • Gastrointestinal bleeding, 591
  • Gastrointestinal cancer, 497
  • Gastrointestinal oncology, 1, 191, 401, 771, 901, 981, 1159
  • Gastrointestinal physiology, 39
  • Gastrointestinal prokinesia, 379
  • Gastro-oesophageal reflux, 95, 931
  • Gene, E. see Gisbert, J.P.
  • General Practice, 917
  • Genschel, J. see Büning, C.
  • Gentile, S. see Angelico, M.
  • GERD, 455, 463, 1041
  • Geremia, A. see Biancone, L.
  • Gessner, U. see Dammann, H.-G.
  • Giacobbe, A. see Mangia, A.
  • Giannini, E.G. & Testa, R. Letter to the Editors, 827
  • Gibson, J.A. see Green, J.R.B.
  • Gimona, A. see Kivitz, A.J.
  • Gisbert, J.P., Khorrami, S., Carballo, F., Calvet, X., Gene, E. & Dominguez-Muñoz, E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer, 617
  • Gisbert, J.P., Trapero, M., Calvet, X., Mendoza, J., Quesada, M., Güell, M. & Pajares, J.M. Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding, 923
  • Glucocorticoid Receptor, 47
  • Gluten-free, 1277
  • Goddard, C.J.R. see Ho, G.T.
  • Goland, S. see Kaptan, K.
  • Goldthorpe, S. see Langmead, L.
  • Gorard, D.A. see Kitiyakara, T.
  • GORD, 253
  • Grace, E. see Chiba, N.
  • Graham, D.Y. see Chan, F.K.L.
  • Graham, D.Y., Laine, L. & Dubois, R.W. Letter to the Editors, 1323
  • Granström, M. see Wheeldon, T.-U.
  • Green tea, 497
  • Green, J.R.B., Swan, C.H.J., Gibson, J.A., Kerr, G.D., Swarbrick, E.T. & Thornton, P.C. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study, 435
  • Greinwald, R. see Herrlinger, K.R.
  • Gremse, D.A., Donnelly, J.R., Kukulka, M.J., Lloyd, E. & Lee, C. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe, 1211
  • Grieco, A. see Angelico, M.
  • Grieco, A. see Cammarota, G.
  • Griffin, J.S. see Freston, J.W.
  • Grol, R. see Krol, N.
  • Grønbæk, K. see Vilien, M.
  • Growth factors, 1019
  • Growth/Development/Nutrition, 245, 583, 1277
  • Güell, M. see Gisbert, J.P.
  • Guidelines, 197
  • Guillemot, F. see Bouhnik, Y.
  • Gulsen, M. see Uygun, A.
  • Guslandi, M. see Brisinda, G.
  • H. pylori, 253, 349, 993, 1181, 1309
  • Haaijer-Ruskamp, F. see Krol, N.
  • Hadziyannis, S.J. see Papatheodoridis, G.V.
  • Hahn, E.G. see Dormann, H.
  • Halder, S.L.S., Locke III, G.R., Talley, N.J., Fett, S.L., Zinsmeister, A.R. & Melton III, L.J. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case–control study, 233
  • Halphen, M. see Brisinda, G.
  • Hammer, J. see Eslick, G.D.
  • Hammer, J. & Schmidt, B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough, 1105
  • Hanauer, S.B. see Sandborn, W.J.
  • Harb, G. see Jensen, D.M.
  • Haruma, K. see Kai, H.
  • Haugk, B. see Aithal, G.P.
  • Hauschildt Juhl, H. see Meineche-Schmidt, V.
  • Hawkey, C. see Kivitz, A.J.
  • HBsAg, 771
  • HCC, 771
  • HCV chronic hepatitis, 331
  • Healing, 359
  • Health economics, 1247
  • Health service research, 191, 1247
  • Heartburn, 95, 463
  • Heikkinen, M. see Koivisto, T.T.
  • Helicobacter, 841
  • Helicobacter pylori, 89, 107, 219, 407, 789, 923, 1009, 1315
  • Henning, J.M. see Dubois, R.W.
  • Heparin, 871
  • Hepatitis, 323
  • Hepatitis C, 1159
  • Hepatitis C virus, 551
  • Hepatitis vaccination, 715
  • Hepatocellular carcinoma, 999, 1301
  • Hepatotoxicity, 391
  • Herba, K. see Barkun, A.N.
  • Herbal, 271
  • Herbal therapy, 739
  • Herdman, C.R. see Schwartz, D.A.
  • Herrlinger, K.R. Fellermann, K., Fischer, C., kreisel, W., Deibert, P., Schoelmerich, J., Fleig, W.E., Ruhl, A., Reinshagen, M., Greinwald, R., Stange, E.F. & Schwab, M. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease, 1269
  • Hertervig, E. see Sturegård, E.
  • Hiatal hernia, 663
  • Hiele, M. see Marchal, L.
  • Higgins, P.D.R., Davis, K.J. & Laine, L. Systematic review: the epidemiology of ischaemic colitis, 729
  • High dose lanzoprazole, 1123
  • Hinterleitner, T.A. see Wenzl, H.H.
  • Ho, G.T., Mowat, C., Goddard, C.J.R., Fennell, J.M., Shah, N.B., Prescott, R.J. & Satsangi, J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery, 1079
  • Ho, P. see Lam, C.-M.
  • Hoang, T.T.H. see Wheeldon, T.-U.
  • Hoes, A.W. see Bijkerk, C.J.
  • Holt, H. see Langmead, L.
  • Holtmann, G. see Madisch, A.
  • Homerin, M. see Galmiche, J.P.
  • Horikawa, Y. see Shimatani, T.
  • Hormone replacement therapy, 563
  • Hormones and Receptors, 47, 687, 695, 797, 805
  • Hospital stay, 63
  • Hosseini, V. see Fakheri, H.
  • Host factors, 219
  • Hotz, J. see Madisch, A.
  • Houghton, L.A. see Calvert, E.L.
  • Howell, S.C. see Eslick, G.D.
  • Hu, P.J. see Xiong, L.S.
  • Hu, W.H.C. see Hui, C.-K.
  • Hu, W.H.C. see Wong, W.M.
  • Huang, J.Q. see Wong, W.M.
  • Huang, Y.-H. see Huo, T.
  • Huang, Y.-H. see Huo, T.-I.
  • Hui, C.-K., Liu, C.-L., Lai, K.-C., Chan, S.-C., Hu, W.H.C., Wong, W.-M., Cheung, W.W., Ng, M., Yuen, M.-F., Chan, A.O., Lo, C.M., Fan, S.-T. & Wong, B.C.Y. Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older, 1153
  • Hui, W.M. see Wong, W.M.
  • Human, 889
  • Hungin, A.P.S. see Panter, S.J.
  • Hungin, A.P.S. see Rubin, G.P.
  • Hunter, M.M. & McKay, D.M. Review article: helminths as therapeutic agents for inflammatory bowel disease, 167
  • Huo, T., Huang, Y.-H., Wu, J.-C., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey, 1301
  • Huo, T.-I., Wu, J.-C., Huang, Y.-H., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Acute renal failure after transarterial chemoem-bolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome, 999
  • Hvenegaard, A. see Meineche-Schmidt, V.
  • HVPG measurement, 571
  • Hyperhomocysteinemia, 107
  • Hyperlipidemia, 1173
  • Hyperprolactinaemia, 379
  • Iacobellis, A. see Mangia, A.
  • IBD, 941
  • IBS visceral hypersensitivity, 123, 271
  • ICAM-1, 281
  • Ierardi, E. see De Francesco, V.
  • Iijima, K., Sekine, H., Koike, T., Imatani, A., Ohara, S. & Shimosegawa, T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria, 1181
  • Iiritano, E. see Zentilin, P.
  • Ileal involvement, 1073
  • Ileal mucosa, 671
  • Ileocecal resection, 1073
  • Imatani, A. see Iijima, K.
  • Immune deviation, 167
  • Immunology and Microbiology, 47, 89, 167, 511, 521, 551, 749, 1009, 1033, 1293
  • Immunosuppression, 427
  • Incontinence, 481
  • Inflammatory bowel disease, 63, 755
  • Inflammatory disorders, 47, 179, 427, 511, 521, 529, 551, 729, 739, 749, 755, 871, 1019, 1063, 1189, 1269
  • Infliximab, 295
  • Infliximab therapy, 1019
  • iNOS IL-6 gastrin, 1309
  • Inoue, M. see Shimatani, T.
  • Insulin resistance, 537
  • Integrated intragastric acidity, 443
  • Interferon, 339
  • Interferon-α, 25
  • Interleukin 6, 671
  • Intestinal disorders, 1, 47, 123, 179, 197, 233, 245, 263, 295, 311, 511, 671, 687, 695, 729, 739, 749, 755, 861, 901, 1009, 1025, 1063, 1079, 1235, 1277
  • Intestinal fibrosis, 1019
  • Intestinal microflora, 889
  • Intragastric pH, 443
  • Intragastric pH> 4, 113
  • Intravenous, 1111
  • Iran, 89
  • Iron deficiency anaemia, 663
  • Irritable bowel syndrome, 133, 263, 271, 1199, 1217
  • Irvine, E.J. see Bloom, S.
  • Isik, A.T. see Uygun, A.
  • Ito, M. see Kai, H.
  • Jacobsen, J. see Nørgård, B.
  • Jain, R. see Malik, A.H.
  • Jansen, J.B.M.J. see Van Rossum, L.G.M.
  • Janssens, J. see Demarchi, B.
  • Jensen, D.M., Cotler, S.J., Lam, H., Harb, G. & Shillington, A. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres, 69
  • Jess, T., Winther, K.V., Munkholm, P., Langholz, E. & Binder, V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark, 287
  • Jewell, D.P. see Langmead, L.
  • Johns, C.E. see Newton, J.L.
  • Johnsen, S.P. see Nørgård, B.
  • Jonderko, K. see Mangel, A.W.
  • Kadayifci, A. see Uygun, A.
  • Kai, H. Ito, M., Kitadai, Y., Tanaka, S., Haruma, K. & Chayama, K. Chronic gastritis with expression of inducible nitric oxide synthase is associated with high expression of interleukin-6 and hypergastrinaemia, 1309
  • Kamerling, I.M.C., Van Haarst, A.D., De Kam, M.L., Cohen, A.F., Masclee, A.A.M. & Burggraaf, J. Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia, 797
  • Kamm, M.A. see Emmanuel, A.V.
  • Kane, S.V. see Loftus Jr, E.V.
  • Kang, J.Y., Dhar, A., Pollok, R., Leicester, R.J., Benson, M.J., Kumar, D., Melville, D., Neild, P.J., Tibbs, C.J. & Maxwell, J.D. Diverticular disease of the colon: ethnic differences in frequency, 765
  • Kaptan, K., Beyan, C., Malnick, S., Goland, S., Rajendra, S. & Alahuddin, S. Letters to the Editors, 703
  • Kasicka-Jonderko, A. see Mangel, A.W.
  • Katz, P.O. see Tutuian, R.
  • Kaukinen, K. see Collin, P.
  • Keeffe, E.B. see Lin, O.S.
  • Keeffe, E.B. see Reiss, G.
  • Kennedy, W. see Barkun, A.N.
  • Kerr, G.D. see Green, J.R.B.
  • Khorrami, S. see Gisbert, J.P.
  • Kiilerich, S. see Bloom, S.
  • Kitadai, Y. see Kai, H.
  • Kitagawa, T. see Yamamoto, T.
  • Kitiyakara, T., Bailey, D.M., McIntyre, A.S. & Gorard, D.A. Adenomatous colonic polyps are rare in ulcerative colitis, 879
  • Kivitz, A.J., Nayiager, S., Schimansky, T., Gimona, A., Thurston, H.J. & Hawkey, C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis, 1189
  • Kling, K. see Büning, C.
  • Klose, G. see Erdmann, J.
  • Klotz, U. see Treiber, G.
  • K-means, 133
  • Knottnerus, J.A. see Bijkerk, C.J.
  • Koike, T. see Iijima, K.
  • Koivisto, T.T., Rautelin, H.I., Voutilainen, M.E., Niemelä, S.E., Heikkinen, M., Sipponen, P.I. & Färkkilä, M.A. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population, 1009
  • k-ras, 1225
  • Kreisel, W. see Herrlinger, K.R.
  • Krol, N., Wensing, M., Haaijer-Ruskamp, F., Muris, J.W.M., Numans, M.E., Schattenberg, G., Van Balen, J. & Grol, R. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial, 917
  • Krüger, S. see Büning, C.
  • Krupp, S. see Dammann, H.-G.
  • Kuebeler, M. see El-Serag, H.B.
  • Kukulka, M.J. see Gremse, D.A.
  • Kumar, D. see Kang, J.Y.
  • Kumar, K.S. see Malik, A.H.
  • Kuroiwa, T. see Shimatani, T.
  • Laboratory signals, 303
  • Ladabaum, U. see Mein, S.M.
  • Laheij, R.J.F. see Van Rossum, L.G.M.
  • Lai, C.L. see Chan, A.O.O.
  • Lai, K.-C. see Hui, C.-K.
  • Lai, K.C. see Wong, W.M.
  • Laine, L. see Dubois, R.W.
  • Laine, L. see Graham, D.Y.
  • Laine, L. see Higgins, P.D.R.
  • Lam, C.L.K. see Wong, W.M.
  • Lam, C.M. see Chan, A.O.O.
  • Lam, C.-M., Chan, A.O.O., Ho, P., Ng, I.O.-L., Lo, C.M., Liu, C.L., Poon, R.T.P. & Fan, S.T. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients — implications for screening, 771
  • Lam, H. see Jensen, D.M.
  • Lam, K.F. see Wong, W.M.
  • Lam, S.K. see Wong, W.M.
  • Lamivudine, 25, 323
  • Langholz, E. see Bloom, S.
  • Langholz, E. see Jess, T.
  • Langmead, L., Feakins, R.M., Goldthorpe, S., Holt, H., Tsironi, E., De Silva, A., Jewell, D.P. & Rampton, D.S. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis, 739
  • Langmead, L., Makins, R.J. & Rampton, D.S. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro, 521
  • Lansoprazole, 455, 1111, 1211
  • Lassen, M.R. see Bloom, S.
  • Lawson, M.J. see Tagore, K.S.
  • Leandro, G. see Mangia, A.
  • Lee, C. see Gremse, D.A.
  • Lee, C.Q. see Freston, J.W.
  • Lee, J. see Chiba, N.
  • Lee, K.-J., Vos, R. & Tack, J. Effects of capsaicin on the sensorimotor function of the proximal stomach in humans, 415
  • Lee, P.-C. see Huo, T.
  • Lee, P.-C. see Huo, T.-I.
  • Lee, S.-D. see Huo, T.
  • Lee, S.-D. see Huo, T.-I.
  • Leicester, R.J. see Courtney, E.D.J.
  • Leicester, R.J. see Kang, J.Y.
  • Leiper, K. see Bloom, S.
  • Lembo, T. see Schwetz, I.
  • Leo, P. see Soncini, M.
  • Leslie, W.D. see Bernstein, C.N.
  • Leung, N.W.-Y. see Wong, V.W.-S.
  • Levin, T.R. see Tagore, K.S.
  • Levine, M.E., Muth, E.R., Williamson, M.J. & Stern, R.M. Protein-predominant meals inhibit the development of gastric tachyarrhythmia, nausea and the symptoms of motion sickness, 583
  • Levy, M. see Dormann, H.
  • Libby, G.W. see Castle, M.Z.D.
  • Lin, O.S., Keeffe, E.B., Sanders, G.D. & Owens, D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C, 1159
  • Lindsay, J.O., Andreyev, H.J.N., Vlavianos, P. & Westaby, D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass, 901
  • Linear height, 253
  • Lipase, 601
  • Lipase inhibitor, 1261
  • Lipiodol, 779
  • Lippl, F. see Erdmann, J.
  • Liu, C.-L. see Hui, C.-K.
  • Liu, C.L. see Lam, C.-M.
  • Liver biopsy, 545
  • Liver cirrhosis, 999, 1301
  • Liver descriptors, 25, 79, 209, 401, 545, 551, 999, 1033, 1159, 1301
  • Liver transplantation, 157
  • Lloyd, E. see Gremse, D.A.
  • Lo Iacono, O. see Apolinario, A.
  • Lo, C.M. see Hui, C.-K.
  • Lo, C.M. see Lam, C.-M.
  • Lochs, H. see Büning, C.
  • Locke III, G.R. see Diaz-Rubio, M.
  • Locke III, G.R. see Halder, S.L.S.
  • Locke III, G.R., Yawn, B.P., Wollan, P.C., Melton III, L.J., Lydick, E. & Talley, N.J. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population, 1025
  • LODT, 1211
  • Loftus Jr, E.V., Kane, S.V. & Bjorkman, D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, 179
  • Lorente, R. see Apolinario, A.
  • Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J.-F. & Watier, H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease, 511
  • Lowson, D. see Bloom, S.
  • Lucey, M.R. see Tome, S.
  • Luckow, A. see Meineche-Schmidt, V.
  • Lumiracoxib, 1189
  • Lydick, E. see Locke III, G.R.
  • Mabisombi, A. see Brisinda, G.
  • Madisch, A., Holtmann, G., Plein, K. & Hotz, J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial, 271
  • Maggiore, G. see Sciveres, M.
  • Magni (on behalf of the Ring Study Group), G. see Soncini, M.
  • Mahida, Y.R. see Austin, A.S.
  • Maintenance treatment, 1147
  • Majano, P.L. see Apolinario, A.
  • Mäki, M. see Collin, P.
  • Makins, R.J. see Langmead, L.
  • Malekzadeh, R. see Fakheri, H.
  • Malet, P.F. see Malik, A.H.
  • Malfertheiner, P. see Treiber, G.
  • Malik, A.H., Kumar, K.S., Malet, P.F., Jain, R., Prasad, P. & Ostapowicz, G. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis, 545
  • Malnick, S. see Kaptan, K.
  • Mangel, A.W., Jonderko, K., Kasicka-Jonderko, A. & Blonska-Fajfrowska, B. Letters to the Editors, 141
  • Mangia, A., Spinzi, G., Vuturo, O., Pazienza, V., Iacobellis, A., Piattelli, M., Giacobbe, A., Leandro, G., Piermanni, V., Minoli, G., Montalto, G. & Andriulli, A. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study, 331
  • Manning criteria, 1217
  • Mansi, C. see Zentilin, P.
  • Marangi, S. see De Francesco, V.
  • Marchal, L., D'Haens, G., Van Assche, G., Vermeire, S., Noman, M., Ferrante, M., Hiele, M., Bueno De Mesquita, M., D'Hoore, A., Penninckx, F. & Rutgeerts, P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study, 749
  • Margiotta, M. see De Francesco, V.
  • Maria, G. see Brisinda, G.
  • Marniga, G. see Brisinda, G.
  • Martin, P. see Firpi, R.J.
  • Martino, A. see Cammarota, G.
  • Masclee, A.A.M. see Kamerling, I.M.C.
  • Mastracci, L. see Zentilin, P.
  • Mathus-Vliegen, E.M.H., Van Ierland-Van Leeuwen, M.L. & Terpstra, A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity, 601
  • Matin, K. see Schwetz, I.
  • Matsumoto, K. see Yamamoto, T.
  • Maxwell, J.D. see Kang, J.Y.
  • May, F.E.B. see Newton, J.L.
  • Mayer, E.A. see Schwetz, I.
  • McCormick, P.A. see O'Keeffe, C.
  • McIntyre, A.S. see Kitiyakara, T.
  • McKay, D.M. see Hunter, M.M.
  • McLaughlin, J.K. see Nørgård, B.
  • Median intragastric pH value, 113
  • Medical Decision Analysis, 191
  • Medical therapy, 295, 511
  • Medical treatment, 953
  • Medication toxicity, 1033
  • Mein, S.M. & Ladabaum, U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis, 1199
  • Meineche-Schmidt, V., Hauschildt Juhl, H., Østergaard, J.E., Luckow, A. & Hvenegaard, A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care, 907
  • Melmed, G.Y. see Dubois, R.W.
  • Melton III, L.J. see Halder, S.L.S.
  • Melton III, L.J. see Locke III, G.R.
  • Melville, D. see Kang, J.Y.
  • Melville, D.M. see Courtney, E.D.J.
  • Mendoza, J. see Gisbert, J.P.
  • Menne, D. see Fox, M.
  • Merat, S. see Fakheri, H.
  • Meta-Analysis, 631
  • Metformin, 537
  • Methodology, 631
  • Methotrexate, 295
  • Methylated 6-thioguanine nucleotides, 1269
  • Metronidazole, 1009
  • MIC, 1315
  • Michel, C. see Bouhnik, Y.
  • Microsatellite instability marker, 1225
  • Middel, P. see Raddatz, D.
  • Miele, L. see Cammarota, G.
  • Minenna, M.F. see De Francesco, V.
  • Miner Jr, P., Wedel, M., Bane, B. & Bradley, J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis, 281
  • Minic´, M. see Brisinda, G.
  • Minoli, G. see Mangia, A.
  • Misoprostol, 1051
  • Moayyedi, P. see Abraham, N.S.
  • Molnar, B. see Ruzsovics, A.
  • Monitoring, 449
  • Moniz, C. see Pereira, S.P.
  • Moniz, C. see Trebble, T.M.
  • Mönnikes, H. see Stanghellini, V.
  • Montalto, G. see Mangia, A.
  • Morbidity, 779
  • Moreno-Elola-Olaso, C. see Diaz-Rubio, M.
  • Morini, S. see De Francesco, V.
  • Motilin, 797
  • Motility and nerve-gut interactions, 95, 123, 271, 311, 415, 583, 601, 687, 695, 805, 861, 1025, 1235, 1261
  • Mowat, C. see Ho, G.T.
  • Mullee, M.A. see Trebble, T.M.
  • Multicenter study, 63
  • Munakata, J. see Schwetz, I.
  • Munck, L.K. see Vilien, M.
  • Munkholm, P. see Jess, T.
  • Muris, J.W.M. see Bijkerk, C.J.
  • Muris, J.W.M. see Krol, N.
  • Muscatiello, N. see De Francesco, V.
  • Mutation analysis, 157
  • Muth, E.R. see Levine, M.E.
  • Mycophenolate mofetil, 427
  • Naliboff, B. see Schwetz, I.
  • Nausea, 583
  • Nayiager, S. see Kivitz, A.J.
  • NCCP, 1123
  • Nedrow, S.I. see Ward, E.M.
  • Neild, P.J. see Kang, J.Y.
  • Neubert, A. see Dormann, H.
  • Neurotensin, 931
  • Neut, C. see Bouhnik, Y.
  • Newton, J.L., Johns, C.E. & May, F.E.B. Review article: the ageing bowel and intolerance to aspirin, 39
  • Ng, F.-H., Wong, B.C.-Y., Wong, S.-Y., Chen, W.-H. & Chang, C.-M. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk — a single-blind, randomized controlled study, 359
  • Ng, I.O.-L. see Lam, C.-M.
  • Ng, M. see Hui, C.-K.
  • Niemelä, S.E. see Koivisto, T.T.
  • Nilsson, L.E. see Wheeldon, T.-U.
  • Nissen, N. see Firpi, R.J.
  • Nista, E.C. see Cammarota, G.
  • Nista, E.C. see Candelli, M.
  • Nista, E.C. see Santarelli, L.
  • Nocturnal acid breakthrough, 655, 1105
  • Nocturnal gastric acid breakthrough (NAB), 113
  • NOD2, 1073
  • Nolan, N. see O'Keeffe, C.
  • Noman, M. see Marchal, L.
  • Nonalcoholic steatohepatitis, 537
  • Non-cardiac chest pain, 1123
  • Non-ulcer dyspepsia, 133, 993
  • Nørgård, B., Pedersen, L., Jacobsen, J., Rasmussen, S.N. & Sørensen, H.T. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception, 679
  • Nørgård, B., Pedersen, L., Johnsen, S.P., Tarone, R.E., McLaughlin, J.K., Friis, S. & Sørensen, H.T. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case–control study, 817
  • Nørregaard, P. see Vilien, M.
  • NSAIDs, 197, 817, 1051
  • Numans, M.E. see Krol, N.
  • Nutrition, 779, 1173
  • O'Keeffe, C., Baird, A.W., Nolan, N. & McCormick, P.A. Cholestatic pruritus – the role of cutaneous mast cells and nerves, 1293
  • O'Morain, C. see Bloom, S.
  • Obesity, 311, 601, 1173
  • Ockenga, J. see Büning, C.
  • O'Donohue, J. see Pereira, S.P.
  • Oesophagus, 449
  • Oesophageal disorders, 907
  • Oesophageal manometry, 931
  • Oesophageal varices, 571
  • Oesophageal / gastric / duodenal disorders, 89, 95, 191, 197, 233, 463, 591, 601, 841, 1009, 1111, 1181, 1189, 1277
  • O'Flanagan, H. see Panter, S.J.
  • Ohara, S. see Iijima, K.
  • Ohning, G. see Schwetz, I.
  • On demand treatment, 907
  • Oral syringe, 1211
  • Orally disintegrating tablet, 1211
  • Orlistat, 311, 601, 1173
  • Orm, S. see Bloom, S.
  • Ostapowicz, G. see Malik, A.H.
  • Osteoporosis, 941
  • Østergaard, J.E. see Meineche-Schmidt, V.
  • Outcome, 981, 1079, 1153
  • Owens, D.K. see Lin, O.S.
  • Ozgurtas, T. see Uygun, A.
  • p53, 1225
  • Paintaud, G. see Louis, E.
  • Pajares, J.M. see Gisbert, J.P.
  • Palla, G. see Sciveres, M.
  • Pallone, F. see Biancone, L.
  • Pancreatic disorders, 901
  • Panella, C. see De Francesco, V.
  • Panter, S.J., O'Flanagan, H., Bramble, M.G. & Hungin, A.P.S. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome, 981
  • Panzuto, F., Di Giulio, E., Capurso, G., Baccini, F., D'Ambra, G., Delle Fave, G. & Annibale, B. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment, 663
  • Papatheodoridis, G.V. & Hadziyannis, S.J. Review article: current management of chronic hepatitis B, 25
  • Parruti, G. see Angelico, M.
  • Paternal drug exposure, 679
  • Patient sample, 133
  • Patient-directed strategy, 917
  • Patients with peristently normal ALT, 331
  • Pazienza, V. see Mangia, A.
  • Pedersen, L. see Nørgård, B.
  • Peginterferon, 551
  • Pelvic floor, 481
  • Penninckx, F. see Marchal, L.
  • Pentoxifylline, 79
  • Peptic ulcer, 359
  • Peptic ulcer disease, 993
  • Percutaneous injection, 1301
  • Pereira, S.P., O'Donohue, J., Moniz, C., Phillips, M.G., Abraha, H., Buxton-Thomas, M. & Williams, R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial, 563
  • Pérez, C. see Apolinario, A.
  • Perianal disease, 427
  • Perianal fistula, 953
  • Perri, F. see Rajendra, S.
  • Petritsch, W. see Wenzl, H.H.
  • Petruzziello, C. see Biancone, L.
  • pH, 449
  • pH monitoring, 1105
  • Pharmaceutical cost, 993
  • Pharmacodynamics, 1111
  • Pharmacogenetics, 511
  • Pharmacokinetics, 1111, 1211
  • Pharmacovigilance, 303
  • Phillips, M.G. see Pereira, S.P.
  • Phuncarg, D.C. see Wheeldon, T.-U.
  • Piattelli, M. see Mangia, A.
  • Piche, T. see Zerbib, F.
  • Piermanni, V. see Mangia, A.
  • Pilgrim, P. see El-Serag, H.B.
  • Pilmer, B.L. see Freston, J.W.
  • Pirozzi, G. see Cammarota, G.
  • Plein, K. see Madisch, A.
  • Pola, P. see Santarelli, L.
  • Pollok, R. see Kang, J.Y.
  • Poluzzi, E. see Tonini, M.
  • Polyps, 879
  • Poon, R.T.P. see Lam, C.-M.
  • Poon, R.T.-P., Yu, W.-C., Fan, S.-T. & Wong, J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial, 779
  • Poordad, F.F. see Firpi, R.J.
  • Population Based Study, 1025
  • Portal hypertension, 79
  • Pouchitis, 281
  • Prasad, P. see Malik, A.H.
  • Prebiotic, 889
  • Prescott, R.J. see Ho, G.T.
  • Primary biliary cirrhosis, 563
  • Primary care, 349, 529, 907
  • Pritchard, D.M. & Przemeck, S.M.C. Review article: how useful are the rodent animal models of gastric adenocarcinoma? 841
  • Proctalgia, 481
  • Profound hypochlorhydria, 1181
  • Proton pump inhibition, 591
  • Proton pump inhibitor(s), 443, 663, 907, 1041, 1051, 1099, 1105
  • Pruritus, 1293
  • Przemeck, S.M.C. see Pritchard, D.M.
  • Quality of life, 529, 1099, 1217
  • Quality of life assessment, 455
  • Quesada, M. see Gisbert, J.P.
  • Questionnaire, 463
  • Rabeprazole, 113
  • Raddatz, D., Middel, P., Bockemühl, M., Benöhr, P., Wissmann, C., Schwörer, H. & Ramadori, G. Glucocorticoid receptor expression in inflammatory to bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis, 47
  • Radiocontrast agent, 999
  • Raines, D.L., Dupont, A.W. & Arguedas, M.R. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding, 571
  • Rajendra, S. see Kaptan, K.
  • Rajendra, S., Alahuddin, S. & Perri, F. Letters to the Editors, 375
  • Ramadori, G. see Raddatz, D.
  • Rampton, D.S. see Langmead, L.
  • Randomised controlled trial, 349, 889
  • Randomised trial, 917
  • Rao, S.S.C. see Tuteja, A.K.
  • Raskine, L. see Bouhnik, Y.
  • Rasmussen, S.N. see Nørgård, B.
  • Rautelin, H.I. see Koivisto, T.T.
  • Record, C.O. see Aithal, G.P.
  • Reflux, 449, 463
  • Reinshagen, M. see Herrlinger, K.R.
  • Reiss, G. & Keeffe, E.B. Review article: hepatitis vaccination in patients with chronic liver disease, 715
  • Relapse, 671
  • Renal failure, 999
  • Reoperation, 1073
  • Resistance, 789
  • Review, 245
  • Review article, 941
  • Rex, D.K. see Chen, S.C.
  • Rey, E. see Diaz-Rubio, M.
  • Rheumatoid arthritis, 1189
  • Ribavirin, 551
  • Richards, C.J. see Todd, J.A.
  • Riottot, M. see Bouhnik, Y.
  • Risk score, 1079
  • Robinson, R.J. see Todd, J.A.
  • Rodriguez-Artalejo, F. see Diaz-Rubio, M.
  • Rofecoxib, 755
  • Rome II criteria, 1217
  • Van Rossum, L.G.M., Laheij, R.J.F., Vlemmix, F., Jansen, J.B.M.J. & Verheugt, F.W.A. Health-related quality of life in patients with cardiovascular disease – the effect of upper gastrointestinal symptom treatment, 1099
  • Rubin, G.P., Hungin, A.P.S., Chinn, D.J. & Dwarakanath, D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey, 529
  • Ruhl, A. see Herrlinger, K.R.
  • Russo, A. see Borrelli, F.
  • Russo, F. see De Francesco, V.
  • Rutgeerts, P. see Louis, E.
  • Rutgeerts, P. see Marchal, L.
  • Ruzsovics, A. Molnar B. Tulassay Z. Review article: deoxyribonucleic acid-based diagnostic techniques to detect Helicobacter pylori, 1137
  • Ryder, S.D. see Austin, A.S.
  • Sabusco, G. see Angelico, M.
  • Sacher-Huvelin, S. see Galmiche, J.P.
  • Saleki, M. see Dammann, H.-G.
  • Sampliner, R.E. see El-Serag, H.B.
  • Sandborn, W.J., Hanauer, S.B. & Buch, A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers, 1089
  • Sanders, G.D. see Lin, O.S.
  • Santarelli, L., Gabrielli, M., Cremonini, F., Santoliquido, A., Candelli, M., Nista, E.C., Pola, P., Gasbarrini, G. & Gasbarrini, A. Atrophic gastritis as a cause of hyperhomocysteinaemia, 107
  • Santoliquido, A. see Santarelli, L.
  • Satiety, 1261
  • Satsangi, J. see Ho, G.T.
  • Savarino, V. see Zentilin, P.
  • Schattenberg, G. see Krol, N.
  • Schimansky, T. see Kivitz, A.J.
  • Schmidt, B. see Hammer, J.
  • Schmidt, H.H.-J. see Büning, C.
  • Schoelmerich, J. see Herrlinger, K.R.
  • Schoenfeld, P. see El-Serag, H.B.
  • Schoenfeld, P. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials, 263
  • Schröder, O., Blumenstein, I., Schulte-Bockholt, A. & Stein, J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine, 295
  • Schulte-Bockholt, A. see Schröder, O.
  • Schulz, H.-U. see Dammann, H.-G.
  • Schürer, M. see Dammann, H.-G.
  • Schusdziarra, V. see Erdmann, J.
  • Schwab, M. see Herrlinger, K.R.
  • Schwabe, M. see Treiber, G.
  • Schwartz, D.A. & Herdman, C.R. Review article: the medical treatment of Crohn's perianal fistulas, 953
  • Schwetz, I., Naliboff, B., Munakata, J., Lembo, T., Chang, L., Matin, K., Ohning, G. & Mayer, E.A. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome, 123
  • Schwizer, W. see Fox, M.
  • Schwörer, H. see Raddatz, D.
  • Sciveres, M., Caprai, S., Palla, G., Ughi, C. & Maggiore, G. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents, 209
  • Screening, 571, 1159, 1225
  • Secondary prophylaxis, 571
  • Second-line medical therapy, 1079
  • Sekine, H. see Iijima, K.
  • Sepulveda, A. see Cremonini, F.
  • Sequential therapy, 407, 993
  • Severe acute pancreatitis, 1153
  • Shackleton, C. see Firpi, R.J.
  • Shah, N.B. see Ho, G.T.
  • Shand, A.G. see Emmanuel, A.V.
  • Shillington, A. see Jensen, D.M.
  • Shimatani, T., Inoue, M., Kuroiwa, T. & Horikawa, Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression, 113
  • Shimosegawa, T. see Iijima, K.
  • Silk, D.B.A. see Castle, M.Z.D.
  • Sinclair, P. see Chiba, N.
  • Single Dose PK, 1089
  • Sipponen, P.I. see Koivisto, T.T.
  • Sjunnesson, H. see Sturegård, E.
  • Somatostatin analogue, 123
  • Soncini, M., Triossi, O., Leo, P. & Magni (on behalf of the Ring Study Group), G. Inflammatory bowel disease and hospital treatment in Italy: the RING multi-centre study, 63
  • Sonnenberg, A. Personal view: going around in circles — circuitous medical management plans, 191
  • Sonnenberg, A. Personal view: patient–physician discordance about benefits and risks in gastroenterology decision-making, 1247
  • Sörberg, M. see Wheeldon, T.-U.
  • Sørensen, H.T. see Nørgård, B.
  • Spaggiari, P. see Zentilin, P.
  • Spinzi, G. see Mangia, A.
  • Sprue, 1199
  • Staging, 391
  • Stange, E.F. see Herrlinger, K.R.
  • Stanghellini, V., Armstrong, D., Mönnikes, H. & Bardhan, K.D. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? 463
  • Stark, M.E. see Ward, E.M.
  • Steatosis, 391
  • Stein, J. see Schröder, O.
  • Stern, R.M. see Levine, M.E.
  • Steroid resistance, 47
  • Stolle, J.C. see Freston, J.W.
  • Stool, 923
  • Stoppino, V. see De Francesco, V.
  • Stroud, M.A. see Trebble, T.M.
  • Study 031, 1089
  • Sturegård, E., Hertervig, E., Sjunnesson, H. & Wadström, T. Letter to the Editors, 613
  • Sturniolo, G.C. see Di Sabatino, A.
  • Stutz, B. see Fox, M.
  • Surgery, 829, 1079
  • Surgical complications, 749
  • Surveillance, 303
  • Survival, 779, 1301
  • Swan, C.H.J. see Green, J.R.B.
  • Swarbrick, E.T. see Green, J.R.B.
  • Symptoms, 219, 463
  • Systematic Review, 631
  • Taccoen, A. see Galmiche, J.P.
  • Tack, J. see Demarchi, B.
  • Tack, J. see Lee, K.-J.
  • Tagore, K.S., Levin, T.R. & Lawson, M.J. Review article: the evolution to stool DNA testing for colorectal cancer, 1225
  • Talley, N.J. see El-Serag, H.B.
  • Talley, N.J. see Eslick, G.D.
  • Talley, N.J. see Halder, S.L.S.
  • Talley, N.J. see Locke III, G.R.
  • Tam, J.S.-L. see Wong, V.W.-S.
  • Tanaka, S. see Kai, H.
  • Tarone, R.E. see Nørgård, B.
  • Tarquini, L. see Angelico, M.
  • Tegaserod, 263
  • Tenatoprazole, 655
  • Terpstra, A. see Mathus-Vliegen, E.M.H.
  • Test and eradicate, 349
  • Testa, R. see Giannini, E.G.
  • Thalidomide, 79
  • Third-line, 789
  • Thomson, A.B.R. see Chiba, N.
  • Thorell, L. see Collin, P.
  • Thornton, P.C. see Green, J.R.B.
  • Threshold analysis, 1247
  • Thumshirn, M. see Fox, M.
  • Thurston, H.J. see Kivitz, A.J.
  • Tibbs, C.J. see Kang, J.Y.
  • Timm, J. see Dammann, H.-G.
  • Tissue tranglutaminase antibody, 1199
  • Todd, J.A., Richards, C.J., Dixon, A. & Robinson, R.J. Gastric ulcer and malignancy – is there a need for follow-up endoscopy? 989
  • Tome, S. & Lucey, M.R. Review article: current management of alcoholic liver disease, 707
  • Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G.R. & De Ponti, F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics, 379
  • Torz, M. see Dammann, H.-G.
  • Tosti, A. see Angelico, M.
  • Tosti, C. see Biancone, L.
  • Tran, T.T. see Firpi, R.J.
  • Transarterial, 779
  • Transient lower oesophageal sphincter relaxations, 931
  • Transplantation, 1033
  • Trapero, M. see Gisbert, J.P.
  • Treatment, 253, 271, 631, 789, 829
  • Trebble, T.M., Wootton, S.A., Stroud, M.A., Mullee, M.A., Calder, P.C., Fine, D.R., Moniz, C. & Arden, N.K. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status, 1063
  • Treiber, G., Schwabe, M., Ammon, S., Walker, S., Klotz, U. & Malfertheiner, P. Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors, 219
  • Triossi, O. see Soncini, M.
  • Triple therapy, 407, 993, 1315
  • Tsironi, E. see Langmead, L.
  • Tulassay, Z. see Ruzsovics, A.
  • Tumor necrosis factor-alpha, 295
  • Tumour necrosis factor, 79
  • Tuteja, A.K. & Rao, S.S.C. Review article: recent trends in diagnosis and treatment of faecal incontinence, 829
  • Tutuian, R., Castell, D.O., Xue, S. & Katz, P.O. The acidity index: a simple approach to the measurement of gastric acidity, 443
  • Tuzun, A. see Uygun, A.
  • Ughi, C. see Sciveres, M.
  • Ulcerative colitis, 179, 879, 1079
  • Ulcers, 1051, 1189
  • Umegae, S. see Yamamoto, T.
  • Uninvestigated dyspepsia, 349
  • Upper gastrointestinal bleeding, 817
  • Upper GI cancer, 981
  • Utility function, 1247
  • Uygun, A., Kadayifci, A., Isik, A.T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M. & Dagalp, K. Metformin in the treatment of patients with non-alcoholic steatohepatitis, 537
  • VacA, 407
  • Vakil, N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease, 1041
  • Van Assche, G. see Marchal, L.
  • Van Balen, J. see Krol, N.
  • Van Gossum, A. see Louis, E.
  • Van Haarst, A.D. see Kamerling, I.M.C.
  • Van Ierland-Van Leeuwen, M.L. see Mathus-Vliegen, E.M.H.
  • Vanilloid receptor, 415
  • Vavasseur, F. see Galmiche, J.P.
  • Veldhuyzen Van Zanten, S.J.O. see Abraham, N.S.
  • Veldhuyzen Van Zanten, S.J.O. see Chiba, N.
  • Verheugt, F.W.A. see Van Rossum, L.G.M.
  • Vermeire, S. see Louis, E.
  • Vermeire, S. see Marchal, L.
  • Vierling, J.M. see Firpi, R.J.
  • Vigneri, S. see Zentilin, P.
  • Vilien, M. Dahlerup J.F. Munck L.K. Nørregaard P. Grønbæk K. Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year, 1147
  • Viral resistance, 25
  • Virologic response, 551
  • Virological response rate, 331
  • Vitamin B12, 107
  • Vlavianos, P. see Lindsay, J.O.
  • Vlemmix, F. see Van Rossum, L.G.M.
  • Vos, R. see Demarchi, B.
  • Vos, R. see Lee, K.-J.
  • Voutilainen, M.E. see Koivisto, T.T.
  • Vuturo, O. see Mangia, A.
  • Wadström, T. see Sturegård, E.
  • Wald, A. see Brisinda, G.
  • Wald, A. see Cheung, O.
  • Walker, S. see Treiber, G.
  • Wang, Q. see Freston, J.W.
  • Wang, W.A. see Xiong, L.S.
  • Ward, E.M., Devault, K.R., Bouras, E.P., Stark, M.E., Wolfsen, H.C., Davis, D.M., Nedrow, S.I. & Achem, S.R. Successful oesophageal pH monitoring with a catheter-free system, 449
  • Watier, H. see Louis, E.
  • Wedel, M. see Miner Jr, P.
  • Weight loss, 1173
  • Wensing, M. see Krol, N.
  • Wenzl, H.H., Hinterleitner, T.A., Aichbichler, B.W., Fickert, P. & Petritsch, W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome, 427
  • Westaby, D. see Lindsay, J.O.
  • Wheeldon, T.-U., Granström, M., Hoang, T.T.H., Phuncarg, D.C., Nilsson, L.E. & Sörberg, M. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication, 1315
  • Whorwell, P.J. see Calvert, E.L.
  • Williams, R. see Pereira, S.P.
  • Williamson, M.J. see Levine, M.E.
  • Wilson disease, 157
  • Winther, K.V. see Jess, T.
  • Wissmann, C. see Raddatz, D.
  • Withdrawal, 1147
  • Wolfsen, H.C. see Ward, E.M.
  • Wollan, P.C. see Locke III, G.R.
  • Wong, B.C.Y. see Chan, A.O.O.
  • Wong, B.C.Y. see Hui, C.-K.
  • Wong, B.C.-Y. see Ng, F.-H.
  • Wong, B.C.Y. see Wong, W.M.
  • Wong, J. see Poon, R.T.-P.
  • Wong, M.L. see Wong, V.W.-S.
  • Wong, N.Y.H. see Wong, W.M.
  • Wong, S.-Y. see Ng, F.-H.
  • Wong, V.W.-S., Chan, H.L.-Y., Wong, M.L., Tam, J.S.-L. & Leung, N.W.-Y. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants 323
  • Wong, W.-M. see Hui, C.-K.
  • Wong, W.M., Lai, K.C., Hui, W.M., Lam, K.F., Huang, J.Q., Hu, W.H.C., Wong, N.Y.H., Lam, C.L.K., Xia, H.H.X., Chan, A.O.O., Lam, S.K. & Wong, B.C.Y. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease, 455
  • Wootton, S.A. see Trebble, T.M.
  • Wu, J.-C. see Huo, T.
  • Wu, J.-C. see Huo, T.-I.
  • Xia, H.H.X. see Wong, W.M.
  • Xiong, L.S., Chen, M.H., Chen, H.X., Xu, A.G., Wang, W.A. & Hu, P.J. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, 1217
  • Xu, A.G. see Xiong, L.S.
  • Xue, S. see Tutuian, R.
  • Yamamoto, T., Umegae, S., Kitagawa, T. & Matsumoto, K. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse, 671
  • Yawn, B.P. see Locke III, G.R.
  • Yesilova, Z. see Uygun, A.
  • YMDD mutants, 323
  • Young screening, 771
  • Yu, W.-C. see Poon, R.T.-P.
  • Yuen, M.F. see Chan, A.O.O.
  • Yuen, M.-F. see Hui, C.-K.
  • Zaru, S. see Angelico, M.
  • Zentilin, P., Mastracci, L., Dulbecco, P., Gambaro, C., Bilardi, C., Ceppa, P., Spaggiari, P., Iiritano, E., Mansi, C., Vigneri, S., Fiocca, R. & Savarino, V. Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring, 1285
  • Zerbib, F., Piche, T., Charles, F., Galmiche, J.-P. & Bruley des Varannes, S. SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans, 931
  • Zinc, 157
  • Zinsmeister, A.R. see Halder, S.L.S.
  • Zullo, A. see De Francesco, V.